Peptide Regulatory News

Latest updates on FDA actions, state regulations, legal cases, and international developments affecting peptide laws.

Federal Regulations March 10, 2026

Why Did Peptide Sciences Shut Down? Timeline, FDA Pressure, and What It Means for the Industry

Peptide Sciences, the largest gray-market research peptide vendor in the U.S., voluntarily shut down on March 6, 2026. A breakdown of the FDA enforcement actions, pharmaceutical lawsuits, and new legislation that led to the closure.

Read Full Article

All News

Legal Analysis March 2, 2026

Australia Peptide Laws: TGA Regulations, Import Rules, and Scheduling

An analysis of Australian peptide laws covering TGA scheduling, import restrictions, and how the regulatory framework compares to the US and UK.

Legal Analysis February 18, 2026

Will Compounded Semaglutide Become Illegal? Patent Law Explained

With Novo Nordisk's semaglutide patents extending into the 2030s, consumers wonder if compounded versions will be banned. We explain how patent law, FDA shortage rules, and pharmacy regulations determine compounded semaglutide's legal future.

Legal Analysis February 18, 2026

Can Peptide Companies Legally Make Health Claims? FDA and FTC Rules

Peptide sellers frequently make bold health claims, but most violate FDA and FTC regulations. Learn what companies can legally claim about peptides and how illegal marketing puts consumers at risk.

Legal Analysis February 18, 2026

Peptide Therapy Side Effects: Your Legal Rights If Something Goes Wrong

When peptide therapy causes harm, patients often don't know their legal options. Learn about liability for peptide therapy injuries, when you can sue, and how to protect your rights if you experience adverse reactions.

Legal Analysis January 26, 2026

Tirzepatide Compounding: Legal Gray Areas Explained

In recent years, the compounding of peptides like Tirzepatide has become a topic of significant debate and intrigue within the pharmaceutical and healthcare industries.

Legal Analysis January 26, 2026

Research Peptide Disclaimers: Do They Provide Legal Protection?

In recent years, research peptides have gained significant attention within the scientific community, offering promising avenues for medical advancements and therapeutic interventions.

Legal Analysis January 26, 2026

WADA and Sports Law: Peptides in Athletic Competition

The intersection of athletic competition and pharmacological enhancement has been a focal point of sports law and ethics for decades.

Legal Analysis January 26, 2026

Personal Importation of Peptides: FDA Guidelines and Risks

The world of pharmaceuticals is evolving, with peptides gaining significant attention in recent years due to their therapeutic potential.

Legal Analysis January 26, 2026

The Legal Status of BPC-157: Not FDA Approved But Not Illegal?

In the rapidly evolving landscape of peptide research and application, BPC-157 stands out as a compound of significant interest. Despite its growing popularity, its legal status remains a topic of debate and confusion.